Streptococcus pseudopneumoniae, an opportunistic pathogen in patients with cystic fibrosis.
Anti-Bacterial Agents
/ therapeutic use
Child
Cystic Fibrosis
/ complications
Cystic Fibrosis Transmembrane Conductance Regulator
/ genetics
Diagnosis, Differential
Female
Humans
Male
Microbiological Techniques
/ methods
Opportunistic Infections
/ diagnosis
Respiratory System
/ microbiology
Sequence Analysis, DNA
/ methods
Streptococcal Infections
/ diagnosis
Streptococcus
/ genetics
Symptom Assessment
Cystic fibrosis
Exacerbation
Identification
Opportunistic pathogen
Resistance
Streptococcus pseudopneumoniae
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
11
08
2019
revised:
31
10
2019
accepted:
11
11
2019
pubmed:
25
11
2019
medline:
14
9
2021
entrez:
25
11
2019
Statut:
ppublish
Résumé
The pathogenic power of Streptococcus pseudopneumoniae has been specified over years, particularly in case of chronic respiratory diseases; S. pseudopneumoniae isolation has however not been characterized before in CF patients. Identification of S. pseudopneumoniae remains challenging due to the high simila-rity level between species of the Streptococcus mitis group. Twenty CF patients with S. pseudopneumoniae were included. Isolates initially identified by phenotypic routine methods were subjected to both recA sequencing and amplification of S. pseudopneumoniae specific markers. Microbiological and clinical data were reviewed for patients with confirmed S. pseudopneumoniae. Thirteen isolates actually belong to S. pseudopneumoniae. S. pseudopneumoniae was associated with pulmonary exacerbation in 46% of the patients, either as the sole pathogen or as part of a polymicrobial infectious process. S. pseudopneumoniae has to be considered as an additional opportunistic pathogen in CF and additional studies are needed to increase knowledge of its epidemiology and clinical significance in CF.
Identifiants
pubmed: 31759908
pii: S1569-1993(19)30966-X
doi: 10.1016/j.jcf.2019.11.004
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28-e31Informations de copyright
Copyright © 2019. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no conflict of interest to declare.